HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!
Farber
Joshua M
JM
Laboratories of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Berger
Edward A
EA
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy; D000998:Antiviral Agents / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D002462:Cell Membrane / Q000378:metabolism; D006678:HIV / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy; D015497:HIV-1 / Q000201:enzymology* / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008954:Models, Biological; D011485:Protein Binding; D019713:Receptors, CCR5 / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism*
D000998:Antiviral Agents; D065100:CCR5 Receptor Antagonists; D008024:Ligands; D019713:Receptors, CCR5; D019718:Receptors, CXCR4